TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21137665

Group type: EXPERIMENTAL
Intervention: 2 hr anesthesia duration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 hr anesthesia duration
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 hr anesthesia duration
Number of subjects: 60
Study: 16334146

Group type: EXPERIMENTAL
Intervention: Isorel
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 11927210

Group type: EXPERIMENTAL
Intervention: Trials with a positive outcome (statistically significant)
Number of subjects: 530
Study: 9579008

Group type: EXPERIMENTAL
Intervention: Intention to screen for colorectal cancer
Number of subjects: 2693

Group type: EXPERIMENTAL
Intervention: Factors associated with intention to screen
Number of subjects: 2693
Study: 7806416

Group type: EXPERIMENTAL
Intervention: Acetate dialysis (AD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bicarbonate dialysis (BD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Lactate hemofiltration (LHF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 15
Study: 2698748

Group type: EXPERIMENTAL
Intervention: Metrizoate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both Metrizoate and Iohexol
Number of subjects: 32
Study: 964138

Group type: EXPERIMENTAL
Intervention: BCG vaccine (Kopenhagen strain) at 160.000 organisms per dose
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: BCG vaccine (Kopenhagen strain) at lower concentrations (22.000, 50.000, 110.000 organisms per dose)
Number of subjects: 217
Study: 30866056

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus bendamustine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP/CVP
Number of subjects: 0
Study: 29468715

Group type: EXPERIMENTAL
Intervention: AZD9977 (5 to 1200 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: AZD9977/eplerenone combination
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fludrocortisone alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 23
Study: 26827266

Group type: EXPERIMENTAL
Intervention: Rufinamide therapy
Number of subjects: 54
Study: 24757219

Group type: EXPERIMENTAL
Intervention: ARV-naive
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: ARV-experienced
Number of subjects: 500

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 500
Study: 22910755

Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents with biodegradable polymer
Number of subjects: 1161

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 1161
Study: 20357504

Group type: EXPERIMENTAL
Intervention: N. sativa seed supplementation (2 g/day orally) for 30 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Specific immunotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (0.1 ml saline solution subcutaneously once a week)
Number of subjects: 24
Study: 17234726

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxypurinol
Number of subjects: 0
Study: 16146597

Group type: EXPERIMENTAL
Intervention: Beating heart under mild hypothermia and CPB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heart arrest by using cold blood cardioplegia and CPB
Number of subjects: 40
Study: 12151429

Group type: EXPERIMENTAL
Intervention: FSH 150 IU only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 37.5 IU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 75 IU
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 150 IU
Number of subjects: 120
Study: 9475135

Group type: EXPERIMENTAL
Intervention: Specific exercise intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 7618621

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 2793755

Group type: EXPERIMENTAL
Intervention: 0.5 ppm of ozone (O3) exposure for 2 hours
Number of subjects: 14
Study: 346427

Group type: EXPERIMENTAL
Intervention: Whole coffee
Number of subjects: 0

Group type: COMPARATOR
Intervention: De-caffeinated coffee
Number of subjects: 0
Study: 28589947

Group type: EXPERIMENTAL
Intervention: EGCG+RES (epigallocatechin‐3‐gallate and resveratrol, 282 and 80 mg/day, respectively)
Number of subjects: 37

Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 37
Study: 25880968

Group type: EXPERIMENTAL
Intervention: Selective Oropharyngeal Decontamination (SOD)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Selective Digestive Decontamination (SDD)
Number of subjects: 5
Study: 23325162

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Dextrose (placebo)
Number of subjects: 173
Study: 21103659

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg and placebo (n=68)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg and aspirin 100 mg (n=63)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Aspirin 100 mg (n=76)
Number of subjects: 207
Study: 19033877

Group type: EXPERIMENTAL
Intervention: EMLA cream (cutaneous anesthesia) applied to the lower leg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 17939194

Group type: EXPERIMENTAL
Intervention: Vegetotropic therapy (Propranolol, Metoclopramid, Atropine)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxic adaptation
Number of subjects: 67
Study: 16083511

Group type: EXPERIMENTAL
Intervention: Ovarian electrocauterization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (ovulatory women with unexplained infertility)
Number of subjects: 36
Study: 12154154

Group type: EXPERIMENTAL
Intervention: Apathy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dementia Severity
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dementia Severity, Executive Dysfunction, Disinhibition
Number of subjects: 29
Study: 11490531

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Pipobroman
Number of subjects: 294

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 294
Study: 7516263

Group type: EXPERIMENTAL
Intervention: Transcatheter oily chemoembolization
Number of subjects: 127

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 127
Study: 2688937

Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories (2800 mg for 3 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Piperaquine phosphate (control)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 56
Study: 7014

Group type: EXPERIMENTAL
Intervention: Lexotan (bromazepam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30761667

Group type: EXPERIMENTAL
Intervention: Patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28792587

Group type: EXPERIMENTAL
Intervention: EMGB
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cyclic NMES
Number of subjects: 42
Study: 25460033

Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (e‐cigs)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Marlboro® cigarettes
Number of subjects: 23
Study: 24320832

Group type: EXPERIMENTAL
Intervention: Adapted Illness Management and Recovery (IMR) program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 97
Study: 21600005

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (MMS) at two times the recommended dietary allowance (RDA)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard of care supplement of 6 multivitamins (MV)
Number of subjects: 214
Study: 19489239

Group type: EXPERIMENTAL
Intervention: Individually designed trans‐fissure approach
Number of subjects: 90
Study: 16685052

Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: Furanocoumarin-free grapefruit juice
Number of subjects: 18
Study: 15273083

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 58
Study: 11763409

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined HRT and Alendronate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy perimenopausal controls
Number of subjects: 80
Study: 9249883

Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide (twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous infusion of furosemide (over 24 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous infusion of furosemide
Number of subjects: 8
Study: 8491934

Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment (amoxicillin, amoxicillin clavulanate potassium, or trimethoprim‐sulfamethoxazole)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No antimicrobial medication
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 96
Study: 3306809

Group type: EXPERIMENTAL
Intervention: Heat treatment combined with radiation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 10
Study: 31280363

Group type: EXPERIMENTAL
Intervention: Integrative body‐mind‐spirit intervention (I‐BMS)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 157
Study: 30150651

Group type: EXPERIMENTAL
Intervention: Home-based stationary cycling during pregnancy (20-36 weeks of gestation)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 84
Study: 27255874

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: S.A.L.T. device
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard laryngoscope
Number of subjects: 236
Study: 24825135

Group type: EXPERIMENTAL
Intervention: Praziquantel 3% ointment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 46
Study: 23586728

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg once daily for 56 days
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo once daily for 56 days
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 20680689

Group type: EXPERIMENTAL
Intervention: Subclinical levels of depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Level of depressed affect and clinical asthma features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of illness burden
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family features and a child missing school
Number of subjects: 0
Study: 17889580

Group type: EXPERIMENTAL
Intervention: Erdosteine 600 mg daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 17277852

Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal with tacrolimus (FK) and mycophenolate mofetil (MMF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy with steroids, cyclosporine and azathioprine or steroids, FK and MMF (Control Group B)
Number of subjects: 56
Study: 12830070

Group type: EXPERIMENTAL
Intervention: parecoxib/valdecoxib
Number of subjects: 462

Group type: COMPARATOR
Intervention: Control
Number of subjects: 462
Study: 11108786

Group type: EXPERIMENTAL
Intervention: TPGDA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: UV‐resin
Number of subjects: 10
Study: 9001824

Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (one capsule daily, 10 days per month, for 3 consecutive months)
Number of subjects: 587
Study: 1355099

Group type: EXPERIMENTAL
Intervention: Retinoic acid (0.1% cream) applied topically for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle treatment applied topically for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Retinoic acid (1 microM) applied to cultured normal human keratinocytes for 4 days
Number of subjects: 12
Study: 3883728

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 10
Study: 29907153

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC)
Number of subjects: 61
Study: 26979631

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to protein kinase C-α (PRKCA)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism related to fms-related tyrosine kinase 1 (FLT1)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to matrix metalloproteinase-2 (MMP2), tissue inhibitor of matrix metalloproteinase-2 (TIMP2), and interleukin 16 (IL16)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to MMP2, matrix metalloproteinase-1 (MMP1), and leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Ancestry estimates
Number of subjects: 833
Study: 24903620

Group type: EXPERIMENTAL
Intervention: Online health behaviour intervention
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Measurement-only control
Number of subjects: 1445
Study: 22339485

Group type: EXPERIMENTAL
Intervention: Vacc‐4x
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 4xCP
Number of subjects: 38
Study: 20191574

Group type: EXPERIMENTAL
Intervention: Pharmacologic and psychosocial treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: New medications
Number of subjects: 100
Study: 18419234

Group type: EXPERIMENTAL
Intervention: Facial emotion recognition task
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ambiguous emotional stimuli
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Interpersonal training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 16084150

Group type: EXPERIMENTAL
Intervention: Tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1760
Study: 12612363

Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (adequate treatment with at least three of five core modules)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (adequate treatment)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (all parents randomised to treatment)
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (treated children)
Number of subjects: 671

Group type: COMPARATOR
Intervention: Control group (344 participants)
Number of subjects: 671
Study: 10565454

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with OI III/IV and/or qualitative collagen defect
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with OI I and/or quantitative collagen defect
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Overall OI patients
Number of subjects: 63
Study: 8743361

Group type: EXPERIMENTAL
Intervention: 3-D video system
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2-D video system
Number of subjects: 30
Study: 1836422

Group type: EXPERIMENTAL
Intervention: Propofol-sufentanil
Number of subjects: 47

Group type: COMPARATOR
Intervention: Enflurane-sufentanil
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 7195247

Group type: COMPARATOR
Intervention: 1 x 20 mg/kg, 2 x 20 mg/kg, or 3 x 20 mg/kg (phase II A trial)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1 x 30 mg/kg (n=53), 1 x 40 mg/kg (n=45), 2 x 20 mg/kg (n=53) (phase II B trial)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Single oral dose of 50 mg/kg (phase II A trial)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Three oral doses of 20 mg/kg given at 4-h intervals (phase II A trial)
Number of subjects: 79

Group type: COMPARATOR
Intervention: 1 x 40 mg/kg (phase II B trial)
Number of subjects: 79
Study: 31937169

Group type: EXPERIMENTAL
Intervention: US-guided excision
Number of subjects: 520

Group type: COMPARATOR
Intervention: Wire-guided excision
Number of subjects: 520
Study: 31296428

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28860511

Group type: EXPERIMENTAL
Intervention: InGaP (GaInP) photon counting X-ray photodiodes; 200 μm diameter; reverse bias above 5 V
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: InGaP (GaInP) photon counting X-ray photodiodes; 400 μm diameter; reverse bias above 5 V
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: System noise analysis
Number of subjects: 4
Study: 25462656

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23625541

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) positivity
Number of subjects: 109

Group type: COMPARATOR
Intervention: Breslow thickness and ulceration status
Number of subjects: 109
Study: 21247310

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy plus axillary dissection
Number of subjects: 3887

Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy alone
Number of subjects: 3887
Study: 19262951

Group type: EXPERIMENTAL
Intervention: Habitual fish consumption
Number of subjects: 867

Group type: COMPARATOR
Intervention: Adjustment for age, gender, and reported age at leaving full-time education
Number of subjects: 867
Study: 17498487

Group type: EXPERIMENTAL
Intervention: General Western medicine therapy and differential treatment of traditional Chinese medicine (TCM) based on stage classification
Number of subjects: 404

Group type: COMPARATOR
Intervention: General Western medicine and placebo of traditional Chinese herbal medicine
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: GCS (Glasgow coma scale)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: NF (Nerve functional failure) scale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: BI (Barther index) scale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: QLI (Quality of life index) scale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: FAQ (Functional activities questionnaire) scale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: ADL (Activity of daily living) scale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: ZH (syndromes of TCM) scale
Number of subjects: 404
Study: 14999563

Group type: EXPERIMENTAL
Intervention: Pattern-recognition methods (artificial neural networks, support vector machine, k-nearest neighbor) applied to MR imaging findings.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Back-propagation artificial neural network
Number of subjects: 430
Study: 12774471

Group type: EXPERIMENTAL
Intervention: Glimepiride (Amaril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride (Amaril) combined with metformin, insulin, repaglynide, and nateglynide
Number of subjects: 0
Study: 10198150

Group type: EXPERIMENTAL
Intervention: EMS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Voluntary (Vol)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Remote EMS (rEMS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 32
Study: 7775504

Group type: EXPERIMENTAL
Intervention: Morphine unit (moderate to high doses of morphine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No-morphine unit (no morphine or morphine derivatives)
Number of subjects: 100
Study: 2107240

Group type: EXPERIMENTAL
Intervention: Terfenadine, 1 mg/kg (mean dose, 69.6 ± 11.2 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 0.12 mg/kg (mean dose, 8.4 ± 1.3 mg)
Number of subjects: 8
Study: 6777801

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.76 ml kg‐1 (orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol at 0.15 ml kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no ethanol)
Number of subjects: 0
Study: 31034261

Group type: EXPERIMENTAL
Intervention: Low-volume eccentric training (1 set per exercise; 10 reps in total)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-volume eccentric training (4 sets; 40 reps)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison between low-volume and high-volume training
Number of subjects: 19
Study: 27841047

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 63
Study: 26353009

Group type: EXPERIMENTAL
Intervention: Metyrapone monotherapy
Number of subjects: 195
Study: 25177431

Group type: EXPERIMENTAL
Intervention: Combination of steroid and Korean red ginseng (KRG)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Steroid therapy alone
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: KRG as an adjuvant to steroid therapy
Number of subjects: 73
Study: 21763393

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Bag-Mask Ventilation (BMV)
Number of subjects: 369
Study: 19523608

Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine VA1.3 (5 x 10(9) CFU)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (diluent buffer)
Number of subjects: 304
Study: 17530295

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus 10(8) CFU/g 1 g b.i.d.)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Antibiotics (trimethoprim/sulfamethoxazole 2/10 mg/kg h.s.)
Number of subjects: 120